Skip to main content

05-02-2018 | Risk factors | News

News in brief

Diabetes risk a concern with hormone therapy for early breast cancer


medwireNews: Research suggests that the increased risk for diabetes seen among survivors of early-stage breast cancer may be driven by hormone therapy.

During an average 5.9 years of follow-up of 2246 survivors of early-stage or regionally advanced invasive breast cancer, the prevalence of diabetes rose from 6% in 2002 to 28% in 2015, with the rate exceeding the national norm from 2010 to 2013.

In multivariate analysis of a subgroup of 57 patients with and 448 without diabetes, use of hormone therapy increased the likelihood for diabetes 2.4-fold, and the researchers calculated that it accounted for 48% of diabetes cases in the cohort overall.

Considering also “the high prevalence of diabetes above national standards [and] the dramatic increase in this prevalence within a relatively brief time,” breast cancer survivors who are given hormone therapy should be monitored for diabetes, advise Hatem Hamood and co-researchers from the Leumit Health Centre in Karmiel, Israel.

Their findings are published in the Journal of Clinical Oncology.

By Eleanor McDermid

medwireNews is an independent medical news service provided by Springer Healthcare. © 2018 Springer Healthcare part of the Springer Nature group


New additions to the Adis Journal Club

A selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

ADA 2022 coverage

Access the latest news and expert insight from the ADA 82nd Scientific Sessions